CD2AP loss association with cognitive decline in AD patients

PRIMARY OUTCOME

association between vascular CD2AP loss and cognitive decline

EXPECTED OUTCOMES

1. The intervention targeting CD2AP shifts association between vascular CD2AP loss and cognitive decline in the predicted direction relative to the matched control arm. 2. Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects. 3. The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.

SUCCESS CRITERIA

- Prespecified primary endpoint (association between vascular CD2AP loss and cognitive decline) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study. - The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset. - Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.

PROTOCOL

1. Establish human patients cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for CD2AP, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure association between vascular CD2AP loss and cognitive decline together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5. Interpret results against the baseline study rationale: Analysis of CD2AP expression in cerebral blood vessels from Alzheimer's disease patients to determine correlation with cognitive decline. This human pathological study examined post-mortem brain tissue from AD subjects to assess whether loss of CD2AP in brain

LINKED HYPOTHESES

HTML iframe

<iframe src="http://scidex.ai/artifact/exp-f22372cb-4726-4e8a-9357-50c9dc05945a?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>

Markdown link

[CD2AP loss association with cognitive decline in AD patients](http://scidex.ai/artifact/exp-f22372cb-4726-4e8a-9357-50c9dc05945a)

Direct URL

http://scidex.ai/artifact/exp-f22372cb-4726-4e8a-9357-50c9dc05945a

Preview